Quantum Break Dev Remedy Entertainment: Going Multi-Platform Has Been a Possibility for Years

Remedy Entertainment wants to release their titles on more than one platform.

Remedy Entertainment is well-known developer with a lot of history for developing stellar titles, and is behind some of the most critically acclaimed games in the industry, such as Max Payne, Max Payne 2, Alan Wake, and most recently, Quantum Break.

Remedy’s Creative Director Sam Lake was recently featured in a video interview with GameReactor, via WCCFTech, where he discussed the studio’s ambition to go multi-platform with their upcoming titles. However, he praised the relationship the studio currently has with Microsoft.

Well, multiplatform for us has obviously been, as an indie developer, something we’ve been thinking about for a long time. I mean, we had a good, long relationship with Microsoft, but creating exclusives for them is creating exclusive content for their platforms.

Now we have the opportunity…As a creator, you always hope that your creation could be there for as big of an audience as possible, and multiplatform obviously makes that possible in a new way. So that was definitely our goal.

Personally, I’m not…We have a brilliant coding team, these days we actually have three tracks running inside Remedy. We have two game projects, we have P7 and then we are working with Smilegate, the Korean publisher, on a story campaign mode for their CROSSFIRE 2, but the third track is actually Northlight. It’s now kind of running on its own and serving both game projects at the same time. Part of the steps we’re working on right now is going multiplatform and PlayStation, especially for that.

This is not the first time Lake expressed his desire to develop for more than just one platform, as he said almost the exact same statement back in May. P7, or Project 7, is Remedy Entertainment’s upcoming title, and is expected to release on PS4, Xbox One and PC. The title still doesn’t have a set release date, but is planned to be a third-person action title.